On Jan. 11, Sanofi Aventis Korea (President Kay Bae) presented a patient drug expense support program to partially cover the cost of Dupixent Prefilled injection 200 mg (dupilumab) prescribed to adolescent patient with atopic dermatitis.

The program aims to contribute in improving the patients’ quality of life by financially supporting the patients with the drug expense, and to allow them to receive the treatment at the right timing.

A topical treatment Dupixent is a first ever biologic drug to be indicated to treat adolescent and adult patients aged 12 years or older with moderate to severe atopic dermatitis. After the 300 mg dose, 200 mg dose was also released to the South Korean ma